No connection

Search Results

RLYB vs ZYBT

RLYB
Rallybio Corporation
BEARISH
Price
$8.22
Market Cap
$43.5M
Sector
Healthcare
AI Confidence
85%
ZYBT
Zhengye Biotechnology Holding Limited
BEARISH
Price
$0.92
Market Cap
$43.6M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
RLYB
--
ZYBT
--
Forward P/E
RLYB
-1.52
ZYBT
--
P/B Ratio
RLYB
0.75
ZYBT
1.01
P/S Ratio
RLYB
50.68
ZYBT
0.28
EV/EBITDA
RLYB
0.35
ZYBT
-66.84

Profitability

Gross Margin
RLYB
0.0%
ZYBT
37.37%
Operating Margin
RLYB
-2888.29%
ZYBT
-46.33%
Profit Margin
RLYB
0.0%
ZYBT
-12.6%
ROE
RLYB
-15.01%
ZYBT
-6.38%
ROA
RLYB
-30.07%
ZYBT
-3.45%

Growth

Revenue Growth
RLYB
484.2%
ZYBT
-34.4%
Earnings Growth
RLYB
--
ZYBT
--

Financial Health

Debt/Equity
RLYB
0.0
ZYBT
0.23
Current Ratio
RLYB
14.51
ZYBT
1.49
Quick Ratio
RLYB
12.96
ZYBT
1.0

Dividends

Dividend Yield
RLYB
--
ZYBT
--
Payout Ratio
RLYB
0.0%
ZYBT
0.0%

AI Verdict

RLYB BEARISH

RLYB exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating a complete lack of financial health across profitability and efficiency metrics. While the company maintains a strong liquidity position with a Current Ratio of 14.51 and zero debt, its operating margin of -2888.29% and a Price/Sales ratio of 50.68 suggest an unsustainable burn rate and extreme overvaluation relative to current revenue. The recent 1-year price surge appears speculative, as it is decoupled from the deterministic health scores and a bearish technical trend of 0/100.

Strengths
Exceptional short-term liquidity (Current Ratio: 14.51)
Zero debt (Debt/Equity: 0.00)
Explosive year-over-year revenue growth (484.20%)
Risks
Severe operational inefficiency (Operating Margin: -2888.29%)
Critical failure in deterministic health (Piotroski F-Score: 0/9)
Extreme valuation premium on sales (P/S: 50.68)
ZYBT BEARISH

ZYBT presents a high-risk profile characterized by a catastrophic price collapse and severe revenue contraction. While the Piotroski F-Score of 5/9 suggests stable internal financial health and the low Debt/Equity ratio (0.23) indicates minimal leverage, these are overshadowed by a -34.40% YoY revenue decline and negative operating margins. The stock is currently trading near its 52-week low after a massive 88.2% one-year decline, signaling a complete loss of investor confidence. Despite a low Price/Sales ratio of 0.28, the lack of growth and profitability makes the current valuation a value trap.

Strengths
Stable Piotroski F-Score (5/9)
Low Debt/Equity ratio (0.23)
Healthy Current Ratio (1.49)
Risks
Severe revenue contraction (-34.40% YoY)
Deeply negative operating margins (-46.33%)
Catastrophic price performance (-88.2% 1Y)

Compare Another Pair

RLYB vs ZYBT: Head-to-Head Comparison

This page compares Rallybio Corporation (RLYB) and Zhengye Biotechnology Holding Limited (ZYBT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile